Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies (Details Narrative)

v3.3.1.900
Significant Accounting Policies (Details Narrative)
12 Months Ended
Apr. 08, 2015
USD ($)
Mar. 09, 2015
USD ($)
Dec. 31, 2015
USD ($)
Breathlyzers
Dec. 31, 2014
USD ($)
Allowance for doubtful accounts receivable     $ 864,000
Allowances charged for doubtful accounts     $ 864,000
Investment in Hainan Savy Akers Biosciences, Ltd. joint venture $ 64,091 $ 64,675    
Percentage of ownership in Hainan Savy Akers Biosciences, Ltd. joint venture     19.90% 28.00%
Deferred revenue     $ 181,293  
Shipping, handling and transportation costs     56,537 $ 35,454
Cost of net revenue     $ 115,423 71,416
Trade Receivable [Member]        
Concentration risk percentage     72.00%  
Concentration risk, number of customer | Breathlyzers     2  
Percentage of customer accounted for trade receivables     28.00%  
Fulton Bank of New Jersey [Member]        
Cash     $ 369,525 399,417
Bank of America [Member]        
Cash     28,494 52,384
PayPal [Member]        
Cash     $ 4,040 $ 4,040
Minimum [Member]        
Normal credit terms extended to customers     30 days  
Maximum [Member]        
Normal credit terms extended to customers     90 days  
Cash, FDIC insured amount     $ 250,000  
Maximum [Member] | Patents [Member]        
Finite-lived intangible asset, useful life     17 years